Literature DB >> 35282770

The role of HMGA1 protein in gastroenteropancreatic neuroendocrine tumors.

Marco De Martino1, Simona Pellecchia1, Francesco Esposito1, Nadia Tosti2, Cristina Quintavalle1,2, Serenella Eppenberger-Castori2, Vincenza Carafa2, Alberto Righi3, Paolo Chieffi4, Alfredo Fusco1,5, Luigi Maria Terracciano6,7, Pierlorenzo Pallante1.   

Abstract

Neuroendocrine tumors (NETs) are neoplasms derived from neuroendocrine cells. One of their main features is to often remain asymptomatic and clinically undetectable. High Mobility Group A (HMGA) proteins belong to a family of non-histone chromatinic proteins able to modulate gene expression through the interaction with DNA and transcription factors. They are overexpressed in most of the human malignancies, playing a critical role in carcinogenesis. However, their expression levels and their role in neuroendocrine carcinogenesis has not been exhaustively evaluated until now. Therefore, in this study, we have addressed the validity of using the expression of HMGA1 as a diagnostic marker and have investigated its role in NET carcinogenesis. The expression of HMGA1 has been evaluated by qRT-PCR and immunohistochemistry, using NET tissue microarrays, in a cohort of gastroenteropancreatic (GEP)-NET samples. The expression levels of HMGA1 have been then correlated with the main clinical features of NET samples. Finally, the contribution of HMGA1 overexpression to NET development has been addressed as far as the modulation of proliferation and migration abilities of NET cells is concerned. Here, we report that HMGA1 is overexpressed in GEP-NET samples, at both mRNA and protein levels, and that the silencing of HMGA1 protein expression interferes with the ability of NET cells to proliferate and migrate through the downregulation of Cyclin E, Cyclin B1 and EZH2. These results propose the HMGA proteins as new diagnostic and prognostic markers.

Entities:  

Keywords:  HMGA1; Neuroendocrine tumors; gastroenteropatic tumors

Mesh:

Substances:

Year:  2022        PMID: 35282770      PMCID: PMC9132388          DOI: 10.1080/15384101.2022.2050646

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   5.173


  31 in total

Review 1.  HMGA1-pseudogene overexpression contributes to cancer progression.

Authors:  Francesco Esposito; Marco De Martino; Floriana Forzati; Alfredo Fusco
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

2.  The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.

Authors:  Daniela D'Angelo; Eleonora Borbone; Dario Palmieri; Sarah Uboldi; Francesco Esposito; Roberta Frapolli; Roberto Pacelli; Maurizio D'Incalci; Alfredo Fusco
Journal:  Eur J Cancer       Date:  2012-11-10       Impact factor: 9.162

3.  DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Authors:  Yuchen Jiao; Chanjuan Shi; Barish H Edil; Roeland F de Wilde; David S Klimstra; Anirban Maitra; Richard D Schulick; Laura H Tang; Christopher L Wolfgang; Michael A Choti; Victor E Velculescu; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos
Journal:  Science       Date:  2011-01-20       Impact factor: 47.728

Review 4.  Roles of HMGA proteins in cancer.

Authors:  Alfredo Fusco; Monica Fedele
Journal:  Nat Rev Cancer       Date:  2007-12       Impact factor: 60.716

5.  Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas.

Authors:  P Arlotta; A K Tai; G Manfioletti; C Clifford; G Jay; S J Ono
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

6.  Overexpression of HMGA1 Figures as a Potential Prognostic Factor in Endometrioid Endometrial Carcinoma (EEC).

Authors:  Antonio Palumbo Júnior; Vanessa Paiva Leite de Sousa; Francesco Esposito; Marco De Martino; Floriana Forzati; Fábio Carvalho de Barros Moreira; Tatiana de Almeida Simão; Luiz Eurico Nasciutti; Alfredo Fusco; Luis Felipe Ribeiro Pinto; Cláudia Bessa Pereira Chaves; Nathalia Meireles Da Costa
Journal:  Genes (Basel)       Date:  2019-05-15       Impact factor: 4.096

7.  MYC-regulated pseudogene HMGA1P6 promotes ovarian cancer malignancy via augmenting the oncogenic HMGA1/2.

Authors:  Xiaoxue Tian; Jianping Song; Xiyu Zhang; Mingyao Yan; Shourong Wang; Yuqiong Wang; Limei Xu; Ling Zhao; Jian-Jun Wei; Changshun Shao; Beihua Kong; Zhaojian Liu
Journal:  Cell Death Dis       Date:  2020-03-03       Impact factor: 8.469

Review 8.  Anatomic and functional imaging of metastatic carcinoid tumors.

Authors:  Andrew F Scarsbrook; Arul Ganeshan; Jane Statham; Rajesh V Thakker; Andrew Weaver; Denis Talbot; Philip Boardman; Kevin M Bradley; Fergus V Gleeson; Rachel R Phillips
Journal:  Radiographics       Date:  2007 Mar-Apr       Impact factor: 5.333

9.  A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness.

Authors:  Silvia Pegoraro; Gloria Ros; Yari Ciani; Riccardo Sgarra; Silvano Piazza; Guidalberto Manfioletti
Journal:  Oncotarget       Date:  2015-08-07

10.  HMGA2 overexpression plays a critical role in the progression of esophageal squamous carcinoma.

Authors:  Antonio Palumbo; Nathalia Meireles Da Costa; Francesco Esposito; Marco De Martino; Daniela D'Angelo; Vanessa Paiva Leite de Sousa; Ivanir Martins; Luiz Eurico Nasciutti; Alfredo Fusco; Luis Felipe Ribeiro Pinto
Journal:  Oncotarget       Date:  2016-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.